The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Analysis of the relationship between Karnofsky performance status (KPS) and tumor response in the RECORD-1 phase III trial of everolimus in patients with advanced renal cell carcinoma (RCC).
C. Porta
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Bayer; Novartis
B. Escudier
Consultant or Advisory Role - Bayer; Pfizer; Roche
T. E. Hutson
Consultant or Advisory Role - Bayer; Genentech; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bayer; Genentech; GlaxoSmithKline; Novartis; Pfizer
R. A. Figlin
Research Funding - Novartis
E. Calvo
Consultant or Advisory Role - Bayer; Novartis; Pfizer; Roche
Honoraria - Bayer; Novartis; Pfizer; Roche
Research Funding - Bayer; Novartis; Pfizer; Roche
V. Grünwald
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Pfizer
Other Remuneration - GlaxoSmithKline; Novartis; Pfizer
S. Osanto
No relevant relationships to disclose
A. Ravaud
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche; Schering-Plough; Wyeth
A. Panneerselvam
Employment or Leadership Position - Novartis
J. J. Knox
Research Funding - Bayer; Novartis; Pfizer
R. J. Motzer
Research Funding - Novartis; Pfizer